Trade Report: Today, John G Ullman & Associates Inc. decides to keep it stake in Johnson & Johnson (JNJ) to the level of $23,420,000

Today, John G Ullman & Associates Inc. decides to keep it stake in Johnson & Johnson (JNJ) to the level of $23,420,000

John G Ullman & Associates Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 22.6% during the third quarter, Holdings Channel reports. The firm owned 198,257 shares of the company’s stock after selling 58,052 shares during the period. Johnson & Johnson accounts for approximately 4.8% of John G Ullman & Associates Inc.’s portfolio, making the stock its largest position. John G Ullman & Associates Inc.’s holdings in Johnson & Johnson were worth $23,420,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Americafirst Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth approximately $101,000. Tuttle Tactical Management LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth approximately $103,000. Lenox Wealth Management Inc. boosted its stake in shares of Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the period. Thomas J. Herzfeld Advisors Inc. boosted its stake in shares of Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares during the period. Finally, NCM Capital Management Group Inc. acquired a new stake in shares of Johnson & Johnson during the second quarter worth approximately $127,000. Institutional investors and hedge funds own 64.13% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) traded down 0.83% during mid-day trading on Monday, reaching $113.18. 4,439,708 shares of the company’s stock were exchanged. The company’s 50 day moving average price is $116.14 and its 200-day moving average price is $118.35. The company has a market capitalization of $307.91 billion, a P/E ratio of 19.87 and a beta of 0.75. Johnson & Johnson has a 52 week low of $94.28 and a 52 week high of $126.07.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.66 by $0.02. The firm earned $17.80 billion during the quarter, compared to the consensus estimate of $17.71 billion. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The company’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.49 EPS. On average, equities research analysts expect that Johnson & Johnson will post $6.72 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 2.80%. The ex-dividend date of this dividend is Friday, November 18th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.29. Johnson & Johnson’s dividend payout ratio is 56.64%.

Several equities research analysts recently issued reports on JNJ shares. Leerink Swann restated a “buy” rating on shares of Johnson & Johnson in a research report on Sunday, September 11th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a research report on Tuesday, September 13th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective for the company in a research report on Monday, August 22nd. Deutsche Bank AG restated a “buy” rating and set a $142.00 price objective on shares of Johnson & Johnson in a research report on Friday, August 19th. Finally, Argus restated a “buy” rating and set a $145.00 price objective on shares of Johnson & Johnson in a research report on Friday, October 21st. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $121.02.

In other Johnson & Johnson news, Director Charles Prince bought 875 shares of the company’s stock in a transaction that occurred on Friday, October 21st. The stock was purchased at an average price of $114.11 per share, with a total value of $99,846.25. Following the transaction, the director now owns 26,520 shares in the company, valued at $3,026,197.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.11% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Related posts

Leave a Comment